Sangamo Therapeutics (Nasdaq: SGMO) has announced it is acquiring TxCell S.A. (ENXTPA: TXCL) in a deal worth approximately €72 million. The deal is expected to be completed by the fourth quarter of 2018.
This acquisition will combine Sangamo’s unique ex vivo (outside the body) gene editing technology with TxCell’s CAR-Treg prowess, making Sangamo a new global leader in the Treg sector. [Read more…]